Article Text

FRI0430 Golimumab in Refractory Uveitis Related To Spondyloarthritis. Multicenter Study of 15 Patients
  1. N. Palmou-Fontana1,
  2. V. Calvo-Río1,
  3. R. Blanco1,
  4. M. Santos-Gomez1,
  5. E. Rubio-Romero1,
  6. M. Cordero-Coma2,
  7. A. Gallego-Flores3,
  8. R. Verόz3,
  9. I. Torre4,
  10. F.F. Hernández5,
  11. A. Atanes6,
  12. J. Loricera1,
  13. M. Gonzalez-Vela1,
  14. J.L. Hernandez7,
  15. M.A. González-Gay1
  1. 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander
  2. 2Ofthalmology, Hospital de Leόn, Leόn
  3. 3Rheumatology, Hospital de Mérida, Badajoz
  4. 4Rheumatology, Hospital de Basurto, Bilbao
  5. 5Rheumatology, Hospital Dr. Negrín, Canarias
  6. 6Rheumatology, Hospital Universitario Complejo a Coruña, A Coruña
  7. 7Internal Medicine, Hospital Universitario Marques de Valdecilla, Santander, Spain


Objectives To assess the efficacy of golimumab (GLM) in refractory uveitis associated to spondyloarthritis (SpA).

Methods Multicenter study of SpA-related uveitis refractory to at least one immunosuppressive drug. The main outcome variables were degree of anterior and posterior chamber inflammation, visual acuity, and macular thickness.

Results Fifteen patients (13 men/2 women; 18 affected eyes; mean age 39±6 years) were evaluated. The underlying SpA subtypes were ankylosing spondylitis (n=8), psoriatic arthritis (n=6) and non-radiographic axial SpA (n=1). The ocular involvement patterns were recurrent anterior uveitis in 8 patients and chronic anterior uveitis in 7. Before GLM they have received methotrexate (n=13), sulfasalazine (n=6), pulses of methylprednisolone (n=4), azathioprine (n=3), leflunomide (n=2) and cyclosporine (n=1). Ten of them had also been treated with TNF-α blockers; etanercept (n=7), adalimumab (n=7), infliximab (n=6), and certolizumab (n=1). GLM was given at the standard dose (50 mg/sc/monthly) as monotherapy (n=7) or in combination with conventional immunosuppressive drugs (n=8), mainly methotrexate. Most patients had rapid and progressive improvement of intraocular inflammation parameters. The median number of cells in the anterior chamber at 2 years (0 [0–0]) was significantly reduced compared to baseline findings (1 [0–3]); p=0.04). The mean best corrected visual acuity value also improved (0.84±0.3 at 2 years versus 0.62±0.3 at baseline; p=0.03). Only minor side effects were observed after a mean follow-up of 23±7 months.

Conclusions Our results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.